Key result
Tasosartan lowers blood pressure at rest and during exercise vs. placebo without impairing working capacity.
Why the study?
The effects of tasosartan on cardiac function, exercise capacity, and regional haemodynamics in patients with essential hypertension were not fully characterized.
Does tasosartan reduce blood pressure and alter regional and systemic haemodynamics in patients with moderate essential hypertension?
RCT (n=24)
Double-blind
crossover
Does tasosartan reduce blood pressure and alter regional and systemic haemodynamics in patients with moderate essential hypertension?
Tasosartan effectively lowers blood pressure and peripheral resistance during submaximal exercise without impairing cardiac output or exercise capacity in hypertensive patients.
Answers are grounded in this paper and cite their sources.
Supports tasosartan for active hypertensives; extends ARB evidence to exercise haemodynamics.
OBJECTIVE: Evaluate the effects of 2 weeks of treatment with tasosartan (1) on cardiac function at rest and during submaximal exercise, (2) on exercise peak oxygen uptake, and (3) on regional haemodynamics at rest in a control condition and during the recovery period of submaximal exercise in patients with essential hypertension. DESIGN AND METHODS: Twenty-four patients with moderate hypertension participated in this randomized, double-blind, crossover, placebo-controlled study. Each patient received tasosartan (100 mg/day) or placebo during two periods of 2 weeks separated by 2 weeks of washout. Ambulatory blood pressure was assessed at the end of each period. Blood pressure, heart rate, cardiac output, stroke volume, total peripheral resistance were measured at rest and during submaximal exercise at the same end points. Regional blood flow and vascular resistance were additionally assessed in the forearm and calf at rest. RESULTS: At rest in the control condition, tasosartan significantly reduced blood pressure although total peripheral resistance, cardiac output and stroke volume as well as forearm and calf vascular resistances were not significantly affected compared to placebo. During submaximal exercise and during the recovery period after submaximal exercise, the reduced blood pressure found with tasosartan was associated with a reduced total peripheral resistance compared to placebo whereas cardiac output, heart rate, or stroke volume were not affected. Peak workload and oxygen uptake were unaffected by tasosartan. CONCLUSIONS: The results of this study indicate that antagonism of the AT1 receptor with tasosartan reduces blood pressure at rest and during submaximal exercise but not during maximal exercise. The reduced blood pressure was associated with a reduced total peripheral resistance during submaximal exercise but not at rest in the control condition while cardiac output was unaltered in either condition. Lastly, tasosartan did not impair working capacity as measured from peak workload and oxygen uptake.
No takes yet. Share an insight, caveat, or question.
Rhéaume et al. (1998) conducted an RCT in essential hypertension (n=24). tasosartan vs. placebo was evaluated on blood pressure, cardiac function, and regional haemodynamics at rest and during submaximal exercise. Tasosartan significantly reduced blood pressure at rest and during submaximal exercise compared to placebo, without impairing working capacity.
Synapse has enriched 10 related papers. Consider them for comparative context: